727993-76-2

Usage

Structure

Pyrrolopyridine derivative with a substituted carbonitrile and methoxy group

Potential applications

Pharmaceutical industry (due to bioactive properties)

Usage

Building block in the synthesis of various drug molecules and organic compounds

Value

Unique structural features make it a valuable tool for medicinal chemistry research and drug discovery efforts.

Upstream product

• 557-21-1 dicyanozinc 
• 727993-75-1 7-bromo-5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine 
• 557-21-1 zinc(II) cyanide 
• 412030-10-5 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine 
• 727993-73-9 2-{5-[(tert-butoxycarbonyl)amino]-2-methoxypyridin-4-yl}ethyl methanesulfonate 
• 727993-72-8 tert-butyl [4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate 
• 727993-74-0 tert-butyl 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 183741-80-2 tert-butyl N-(6-methoxypyridin-3-yl)carbamate 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 

Downstream Products

• 727993-77-3 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-7-yl(phenyl)methanone 
• 727993-81-9 N-(4-methoxy-9-oxo-6-phenyl-1,2,8,9-tetrahydro-5,7,9a-triaza-benzo[cd]azulen-8-yl)-nicotinamide 
• 727993-79-5 8-azido-4-methoxy-6-phenyl-1,2-dihydro-8H-5,7,9a-triaza-benzo [cd] azulen-9-one 
• 727993-80-8 8-Amino-4-methoxy-6-phenyl-1,2-dihydro-8H-5,7,9a-triaza-benzo[cd]azulen-9-one 
• 727993-78-4 4-methoxy-6-phenyl-1,2-dihydro-8H 5,7,9a-triaza-benzo[cd]azulen-9-one 

Relevant academic research and scientific papers

Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors

The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.

Azabenzodiazepines as pde4 inhibitors

Compounds of formula (I): characterized in that:R1 represents a group selected from hydrogen atom, methyl, methoxy, hydroxy, amino, dimethylamino, acetamido, pyrrolidin-1-yl, and hydroxymethyl;R2 represent a group selected from phenyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, indolyl, pyrolyl, [1,2,3]-triazolyl, benzo[c]isoxazolyl, thienyl, pyrazolyl, isothiazolyl, imidazolyl, benzofuranyl, pyrazolo[5,1-c][1,2,4]triazyl each of these groups being optionally substituted from 1 to 3 groups, identical or different independently of each other, selected from halogen, trifluoromethyl, (C1-C4)alkyl, (C1-C4)alkoxy, hydroxy, amino, acetamido, tert-butyloxycarbonylamino, cycloalkylcarbonylamino, sulfonamide, nitro, acetylmethoxy, cyclopentyloxy; optionally, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as active ingredient in pharmaceutical composition useful for treating diseases involving therapy by inhibition of PDE4.